Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 8Neoplasms 4Prostate Cancer Metastatic 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Cancer 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Malignant Solid Tumor - Malignant Nervous System Neoplasm 1Lymphadenopathy 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Prednisone 5enzalutamide 4cabazitaxel 4Docetaxel 3XRP6258 2Abiraterone Acetate 2sipuleucel-T 1rucaparib 1olaparib 1apalutamide 1Zuclomiphene 1Standard of Care 1Prednisolone 1Lenograstim 1LY3023414 1Injections 1Hematologic Tests 1Granulocyte Colony-Stimulating Factor 1Abituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Prostate Cancer Metastatic × XRP6258 × Clear all
NCT02961257 2022-05-12

CABASTY

Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie

Phase 3 Completed
196 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT01718353 2017-11-20

TAXYNERGY

Sanofi

Phase 2 Completed
63 enrolled 13 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡